How will the price of Eisai and Biogen's Leqembi impact Medicare? Sen. Sanders wants to know

Five weeks after getting no response from the U.S. Department of Health and Human Services on his request for more information on the potential financial impact of Eisai and Biogen’s newly approved Alzheimer’s treatment Leqembi, Sen. Bernie Sanders (I-Vt.) is applying more pressure.